Skip to content

Screening and Natural History: Primary Lateral Sclerosis and Related Disorders

Screening and Natural History: Primary Lateral Sclerosis and Related Disorders

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00015444
Enrollment
189
Registered
2001-04-19
Start date
2001-05-01
Completion date
2019-04-24
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Lateral Sclerosis

Keywords

Apparently Sporadic Spastic Paraplegia, Spasticity, Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Muscle Stiffness, Involuntary Muscle Contraction, Isaacs Syndrome

Brief summary

Objective: The objectives of this protocol are: to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, to characterize the natural history of neurodegenerative disorders with corticospinal neuron degeneration, to investigate proposed etiologies, risk factors, and biomarkers for the development of these disorders and for disease progression Study Population: 240 patients with adult-onset progressive spasticity with a diagnosis of primary lateral sclerosis or related upper motor neuron disorder Design: Patients who have been referred by physicians for primary lateral sclerosis will undergo a screening evaluation at the first visit. The screening visit will include review of outside medical records, neurological examination, and diagnostic testing to determine possible causes of spasticity. Patients fulfilling the clinical criteria for primary lateral sclerosis by history or examination will be followed to determine the natural history of this disorder. Measures of motor and cognitive function will be made at baseline and follow-up visits to follow clinical progression. Magnetic resonance imaging will be carried out to determine if imaging changes occur over time. Patients identified in this protocol who are eligible for other research protocols will be invited to participate in additional protocols. Outcome Measures: Clinical progression will be documented by measures of finger-tapping, timed gait, speech. The association between clinical progression and MRI measures will be assessed as a secondary outcome....

Detailed description

Objective: The objectives of this protocol are: * to develop and maintain a repository of clinically characterized patients with primary lateral sclerosis for future research protocols, * to characterize the natural history of neurodegenerative disorders with corticospinal neuron degeneration, * to investigate proposed etiologies, risk factors, and biomarkers for the development of these disorders and for disease progression Study Population: 240 patients with adult-onset progressive spasticity with a diagnosis of primary lateral sclerosis or related upper motor neuron disorder Design: Patients who have been referred by physicians for primary lateral sclerosis will undergo a screening evaluation at the first visit. The screening visit will include review of outside medical records, neurological examination, and diagnostic testing to determine possible causes of spasticity. Patients fulfilling the clinical criteria for primary lateral sclerosis by history or examination will be followed to determine the natural history of this disorder. Measures of motor and cognitive function will be made at baseline and follow-up visits to follow clinical progression. Magnetic resonance imaging will be carried out to determine if imaging changes occur over time. Blood samples may be collected for measurement of potential etiologies of PLS, including risk factor genes. Patients identified in this protocol who are eligible for other research protocols will be invited to participate in additional protocols. Outcome Measures: Clinical progression will be documented by measures of finger-tapping, timed gait, speech. The association between clinical progression and MRI measures will be assessed as a secondary outcome.

Interventions

None listed

Sponsors

National Institute of Neurological Disorders and Stroke (NINDS)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: * Age 18 years of age or older * Adult onset of progressive spasticity * No family history of a similar disorder * Able to provide consent or with a legally-authorized representative who can provide consent

Exclusion criteria

* History of stroke, cerebral palsy, traumatic brain injury or other known etiology of spasticity * Non-neurological disorders producing muscle stiffness, such as fasciitis or rheumatological conditions * Disorders in which pain limits the ability to move muscles, such as fibromyalgia or complex regional pain syndromes * Profound weakness of voluntary movement * Inability to travel to NIH * Anticoagulation will be an exclusion for needle EMG studies * Implanted devices or metal fragments in the brain or spinal cord will be an exclusion for MRI scanning

Design outcomes

Primary

MeasureTime frame
The primary outcome of this protocol is to document the natural history of clinical progression in PLS, defined as the change in clinical measures of movement speed over time: finger tapping, timed gait, and time to read a standard passage.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026